Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Author:

Stilgenbauer Stephan1ORCID,Bosch Francesc2,Ilhan Osman3,Kisro Jens4,Mahé Béatrice5,Mikuskova Eva6,Osmanov Dzhelil7,Reda Gianluigi8,Robinson Sue9,Tausch Eugen10,Turgut Mehmet11,Wójtowicz Marcin12,Böttcher Sebastian13,Perretti Thomas14,Trask Peter15,Van Hoef Marlies16,Leblond Véronique17,Foà Robin18ORCID

Affiliation:

1. Department of Internal Medicine III Ulm University, Ulm and Innere Medizin IUniversitätsklinikum des Saarlandes Homburg Germany

2. Department of Hematology University Hospital Vall d’Hebron Barcelona Spain

3. Internal Medical Sciences Departments Ankara University School of Medicine Ankara Turkey

4. Onkologische Schwerpunktpraxis Lübeck Lübeck Germany

5. Clinical Hematology CHU Nantes Hôtel‐Dieu Nantes France

6. Department of Hemato‐oncology II National Cancer Institute Bratislava Slovakia Blokhin

7. Cancer Research Center Russian Academy of Medical Sciences Moscow Russian Federation

8. UOC Ematologia – Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano Italy

9. QEII Health Sciences Centre Halifax NS Canada

10. Department of Internal Medicine III Ulm University Ulm Germany

11. Department of Internal Medical Sciences Ondokuz Mayis University Samsun Turkey

12. Clinical Department of Hematology Hematological Oncology and Internal Diseases Szpital Wojewodski Opole Poland

13. Department III of Internal Medicine Rostock University Medical CenterRostock (current affiliation) and University Hospital Schleswig‐Holstein Kiel Germany

14. PDB Biostatistics –Medical Affairs F. Hoffmann‐La Roche Ltd Basel Switzerland

15. Patient Centered Outcomes Research Genentech Inc South San Francisco CA USA

16. Global Product Development – Medical Affairs F. Hoffmann‐La Roche Ltd Basel Switzerland

17. Clinical Hematology Sorbonne UniversitéAP‐HP Hôpital Pitié Salpêtrière Paris France

18. Division of Hematology Sapienza University Rome Italy

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3